ArticleEuropean journal of medical research2026
Global, regional, and national burden of lymphoma from 1990 to 2021: a comprehensive analysis based on the global burden of disease study 1990-2021.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma.American journal of hematology · 2026Trial
- Distribution patterns and prediction of lymph, hematopoietic and related tissue cancer incidence in Chinese cancer registration areas from 2005 to 2050.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeBased on the global burden of disease (GBD) data from 1990 to 2021, to systematically evaluate the spatiotemporal variation characteristics of the incidence, mortality, and disability-adjusted life years (DALYs) of lymphoma and its main subtypes (Hodgkin's lymphoma [HL], non-Hodgkin's lymphoma [NHL], and their subtypes). And explore the influence of the sociodemographic index (SDI) on the disease burden of lymphoma.
methodsUsing the GBD 2021 data covering 204 countries/regions worldwide, the age-standardized incidence rate (ASIR), mortality rate (ASDR), DALYs, and average annual percentage change rate (EAPC) were analyzed. The influence of socio-economic factors on the burden of lymphoma was revealed through SDI stratification, regional comparison, and gender-age analysis.
resultsThe results showed that the incidence and mortality rates of HL and NHL in areas with high SDI were relatively high and on the rise, which might be related to the improvement of medical diagnosis levels. The burden of NHL in medium- and low-SDI regions is relatively low but gradually increasing. The incidence of Burkitt lymphoma (BL) and DALYs significantly increased in areas with high SDI, while the changes were relatively small in areas with medium and low SDI. The incidence and mortality rates of most subtypes in men are higher than those in women, and the burden varies significantly among different age groups.
conclusionThe socioeconomic level is closely related to the disease burden of lymphoma. It is necessary to strengthen global medical collaboration and resource allocation, especially to enhance the diagnosis and treatment capabilities in areas with low SDI. In the future, it is necessary to explore the interaction between environmental and genetic factors on lymphoma and formulate precise regional prevention and control strategies in order to reduce the disease burden and promote health equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.